English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduBackground: Our findings explain one of the molecular mechanisms of FXR1’s reported tumorigenic role in HNSCC and lay the groundwork for future research into how targeting the interface between FXR1 and PRMT5 can affect gene expression and aid in the development…
Tag: Cancer Cell
Combined therapy makes headway for liver cancer
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center.
Scientists Track ‘Doubling’ in Origin of Cancer Cells
Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.
Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell Lung Cancer
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
“Gates of Heaven” calcium channel drives oral cancer pain and growth
An essential protein that acts as a gatekeeper for calcium entering cells promotes the growth of oral cancer and generates pain, according to a new study published in Science Signaling led by researchers at NYU College of Dentistry.
Breast cancer cells use forces to open up channels through tissue
New method uses nanospheres to measure forces that cancer cells use to spread through tissue
Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
First in the World! Chulalongkorn Hospital Successfully Treats a Breast Cancer Patient with Immunotherapy
Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society (Chulalongkorn Hospital) has become the world’s first institution to have successfully used immunotherapy to treat a breast cancer patient who is now in complete remission with minimal side effects and uplifted quality of life.
Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
Calcium bursts kill drug-resistant tumor cells
Researchers reporting in ACS’ Nano Letters have developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR.
Genetic discovery delivers new hope for aggressive breast cancers
Groundbreaking cancer research by the University of South Australia has identified an invasive protein molecule that could be responsible for some of the most aggressive breast cancers.
Bacteria in Cancer Cells May Help or Hinder Treatment
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.